vasopressin + epoprostenol

Vasopressin + epoprostenol is a combination of two intravenous agents sometimes used in critical care and perioperative settings, particularly in patients with pulmonary arterial hypertension (PAH) or primary pulmonary hypertension (PPH). Epoprostenol is a synthetic prostacyclin analog that acts as a potent vasodilator and inhibitor of platelet aggregation, primarily used to treat PAH by relaxing blood vessels in the lungs and reducing right heart workload. Vasopressin is an endogenous antidiuretic hormone with strong vasoconstrictive properties via V1 receptors on vascular smooth muscle, often used to support systemic blood pressure during anesthesia or shock. The rationale for combining these drugs may include maintaining systemic perfusion pressure (via vasopressin) while providing selective pulmonary vasodilation and antiplatelet effects (via epoprostenol), especially when catecholamines are undesirable due to their potential to increase pulmonary vascular resistance[1][3][4]. This combination does not have an established brand name or fixed-dose formulation; it is typically administered as separate infusions tailored to individual patient needs.

Brand names

None known for the combination

Other names

None known for the combination